Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Glial Cells

Glial Cells

The Blood-brain Barrier

The Blood-brain Barrier

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Intraocular Pressure Measurement Variability in the Ocular Hypertension Treatment Study.

Ophthalmology. Glaucoma·2026

Same author

Optimal Dimension of Peripheral Iridotomy for Anatomical Efficacy in Primary-Angle-Closure Disease.

Vision (Basel, Switzerland)·2026

Same author

Firecracker injury induced acute secondary angle closure.

Eye (London, England)·2026

Same author

Authors' Response to Comment on: "Travel and financial burdens of cataract surgical care in South India: Comparison of postoperative follow-up at local vision centers versus an urban eye hospital".

Indian journal of ophthalmology·2026

Same author

Family Screening in Glaucoma: A Scoping Review.

Ophthalmology. Glaucoma·2026

Same author

Characterization of Temporal Delay and Modeling of Intraocular Pressure and Visual Field Progression in the African Descent and Glaucoma Evaluation Study.

Ophthalmology. Glaucoma·2026

Same journal

Eye injury rates and community cost savings through vision centers: Evidence from southern India.

Indian journal of ophthalmology·2026

Same journal

Evaluation of the protective efficiency of polycarbonate goggles against firecracker-related ocular injuries.

Indian journal of ophthalmology·2026

Same journal

Comment on: Clinical characteristics, risk factor analysis, and outcomes of graft rejection after Descemet membrane endothelial keratoplasty.

Indian journal of ophthalmology·2026

Same journal

Issue regarding E Log book for PG students: Paper to pixels.

Indian journal of ophthalmology·2026

Same journal

Methylation matters: A case control study on epigenetic alteration in diabetic retinopathy.

Indian journal of ophthalmology·2026

Same journal

Understanding the disconnect: A pilot study of public perception versus reality of corneal donation in India.

Indian journal of ophthalmology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Oct 5, 2025

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

Neuroprotection in glaucoma.

C R Vishwaraj¹, Srinivasan Kavitha¹, Rengaraj Venkatesh¹

¹Department of Glaucoma, Aravind Eye Hospital, Pondicherry, India.

Indian Journal of Ophthalmology

|January 28, 2022

Summary

This summary is machine-generated.

Neuroprotective therapies aim to prevent retinal ganglion cell damage in glaucoma beyond intraocular pressure (IOP) control. Research is exploring novel drug targets for glaucoma neuroprotection, though clinical evidence is still developing.

Keywords:

Glaucoma neuroprotection pharmaceutical agents

More Related Videos

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina

Published on: July 15, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Related Experiment Videos

Last Updated: Oct 5, 2025

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina

Published on: July 15, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Area of Science:

Ophthalmology
Neuroscience
Pharmacology

Background:

Glaucoma progression can occur despite controlled intraocular pressure (IOP).
Factors beyond IOP, such as ischemia, oxidative stress, and neurotoxicity, contribute to retinal ganglion cell apoptosis and optic nerve damage.
Current understanding suggests multiple pathways involved in glaucoma pathogenesis.

Purpose of the Study:

To review current neuroprotection treatment options for glaucoma.
To explore emerging drugs targeting various neuroprotective pathways.
To highlight challenges in clinical translation of neuroprotective agents.

Main Methods:

Literature review of current and investigational neuroprotective therapies for glaucoma.
Analysis of potential therapeutic targets including glutamate excitotoxicity, nitric oxide synthase, and the rho-kinase pathway.
Examination of clinical evidence for drug efficacy beyond IOP reduction.

Main Results:

Several neuroprotective targets are under investigation, including those related to apoptosis mediators, ischemic changes, ocular blood flow, and neurotoxins.
Existing IOP-lowering treatments offer some neuroprotection but have limitations.
Clinical studies evaluating novel neuroprotective agents show limited efficacy to date.

Conclusions:

Neuroprotection is a critical area for managing glaucoma progression, especially when IOP is controlled.
Identifying and validating new therapeutic targets is essential for developing effective glaucoma treatments.
Further clinical research is needed to establish the efficacy of investigational neuroprotective drugs.